Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives

Pain remains common in the setting of malignancy, occurring as a consequence of cancer and its treatment. Several high-quality studies confirm that more than 50% of all patients with cancer experience moderate to severe pain. The prevalence of pain in cancer survivors is estimated to be 40%, while c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American Society of Clinical Oncology educational book 2017-05, Vol.37 (37), p.705-713
Hauptverfasser: Bennett, Mike, Paice, Judith A, Wallace, Mark
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 713
container_issue 37
container_start_page 705
container_title American Society of Clinical Oncology educational book
container_volume 37
creator Bennett, Mike
Paice, Judith A
Wallace, Mark
description Pain remains common in the setting of malignancy, occurring as a consequence of cancer and its treatment. Several high-quality studies confirm that more than 50% of all patients with cancer experience moderate to severe pain. The prevalence of pain in cancer survivors is estimated to be 40%, while close to two-thirds of those with advanced disease live with pain. Progress has occurred in the management of cancer pain, yet undertreatment persists. Additionally, new challenges are threatening these advances. These challenges are numerous and include educational deficits, time restraints, and limited access to all types of care. New challenges to access are occurring as a result of interventions designed to combat the prescription drug abuse epidemic, with fewer clinicians willing to prescribe opioids, pharmacies reluctant to stock the medications, and payers placing strict limits on reimbursement. A related challenge is our evolving understanding of the risks of long-term adverse effects associated with opioids. And reflective of the opioid abuse epidemic affecting the general population, the potential for misuse or abuse exists in those with cancer. Guidelines have been developed to support oncologists when prescribing the long-term use of opioids for cancer survivors. The challenges surrounding the use of opioids, and the need for safe and effective alternative analgesics, are leading to intense interest in the potential benefits of cannabis for cancer-related pain. Oncologists are faced with questions regarding the types of cannabis available, differences between routes of administration, data concerning safety and efficacy, and legal and regulatory dynamics.
doi_str_mv 10.1200/edbk_180469
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1200_EDBK_180469</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28561731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1671-9690bc7b447b53f1eb197992ba3521dce0fcfe3d51b26c678c23b1837203bee63</originalsourceid><addsrcrecordid>eNo9kEtLw0AUhQdRbK2u3Ev2Gp07k8zDXRPrAwsV0XWYmdzA2DYNM1Hw35vS2tV3D3xcOIeQS6C3wCi9w9ouK1A0E_qIjCHPVKpkLo4Pd6ZG5CzGL0oF00yekhFTuQDJYUyKN-PbxLR1suj8xtcxGWJpWodhQMD7pMAWG9_Hm-Tdx-WArTxd9Rha0_sfjOfkpDGriBd7Tsjn4-yjfE7ni6eXcjpPHQgJqRaaWidtlkmb8wbQgpZaM2t4zqB2SBvXIK9zsEw4IZVj3ILiklFuEQWfkOvdXxc2MQZsqi74tQm_FdBqu0Q1eyhe90sM9tXO7r7tGuuD-1-d_wFAf1eX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Bennett, Mike ; Paice, Judith A ; Wallace, Mark</creator><creatorcontrib>Bennett, Mike ; Paice, Judith A ; Wallace, Mark</creatorcontrib><description>Pain remains common in the setting of malignancy, occurring as a consequence of cancer and its treatment. Several high-quality studies confirm that more than 50% of all patients with cancer experience moderate to severe pain. The prevalence of pain in cancer survivors is estimated to be 40%, while close to two-thirds of those with advanced disease live with pain. Progress has occurred in the management of cancer pain, yet undertreatment persists. Additionally, new challenges are threatening these advances. These challenges are numerous and include educational deficits, time restraints, and limited access to all types of care. New challenges to access are occurring as a result of interventions designed to combat the prescription drug abuse epidemic, with fewer clinicians willing to prescribe opioids, pharmacies reluctant to stock the medications, and payers placing strict limits on reimbursement. A related challenge is our evolving understanding of the risks of long-term adverse effects associated with opioids. And reflective of the opioid abuse epidemic affecting the general population, the potential for misuse or abuse exists in those with cancer. Guidelines have been developed to support oncologists when prescribing the long-term use of opioids for cancer survivors. The challenges surrounding the use of opioids, and the need for safe and effective alternative analgesics, are leading to intense interest in the potential benefits of cannabis for cancer-related pain. Oncologists are faced with questions regarding the types of cannabis available, differences between routes of administration, data concerning safety and efficacy, and legal and regulatory dynamics.</description><identifier>ISSN: 1548-8748</identifier><identifier>EISSN: 1548-8756</identifier><identifier>DOI: 10.1200/edbk_180469</identifier><identifier>PMID: 28561731</identifier><language>eng</language><publisher>United States</publisher><subject>Analgesics, Opioid - therapeutic use ; Humans ; Neoplasms - complications ; Neoplasms - physiopathology ; Pain - etiology ; Pain - physiopathology ; Pain Management ; Risk Factors</subject><ispartof>American Society of Clinical Oncology educational book, 2017-05, Vol.37 (37), p.705-713</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1671-9690bc7b447b53f1eb197992ba3521dce0fcfe3d51b26c678c23b1837203bee63</citedby><cites>FETCH-LOGICAL-c1671-9690bc7b447b53f1eb197992ba3521dce0fcfe3d51b26c678c23b1837203bee63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3729,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28561731$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bennett, Mike</creatorcontrib><creatorcontrib>Paice, Judith A</creatorcontrib><creatorcontrib>Wallace, Mark</creatorcontrib><title>Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives</title><title>American Society of Clinical Oncology educational book</title><addtitle>Am Soc Clin Oncol Educ Book</addtitle><description>Pain remains common in the setting of malignancy, occurring as a consequence of cancer and its treatment. Several high-quality studies confirm that more than 50% of all patients with cancer experience moderate to severe pain. The prevalence of pain in cancer survivors is estimated to be 40%, while close to two-thirds of those with advanced disease live with pain. Progress has occurred in the management of cancer pain, yet undertreatment persists. Additionally, new challenges are threatening these advances. These challenges are numerous and include educational deficits, time restraints, and limited access to all types of care. New challenges to access are occurring as a result of interventions designed to combat the prescription drug abuse epidemic, with fewer clinicians willing to prescribe opioids, pharmacies reluctant to stock the medications, and payers placing strict limits on reimbursement. A related challenge is our evolving understanding of the risks of long-term adverse effects associated with opioids. And reflective of the opioid abuse epidemic affecting the general population, the potential for misuse or abuse exists in those with cancer. Guidelines have been developed to support oncologists when prescribing the long-term use of opioids for cancer survivors. The challenges surrounding the use of opioids, and the need for safe and effective alternative analgesics, are leading to intense interest in the potential benefits of cannabis for cancer-related pain. Oncologists are faced with questions regarding the types of cannabis available, differences between routes of administration, data concerning safety and efficacy, and legal and regulatory dynamics.</description><subject>Analgesics, Opioid - therapeutic use</subject><subject>Humans</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - physiopathology</subject><subject>Pain - etiology</subject><subject>Pain - physiopathology</subject><subject>Pain Management</subject><subject>Risk Factors</subject><issn>1548-8748</issn><issn>1548-8756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLw0AUhQdRbK2u3Ev2Gp07k8zDXRPrAwsV0XWYmdzA2DYNM1Hw35vS2tV3D3xcOIeQS6C3wCi9w9ouK1A0E_qIjCHPVKpkLo4Pd6ZG5CzGL0oF00yekhFTuQDJYUyKN-PbxLR1suj8xtcxGWJpWodhQMD7pMAWG9_Hm-Tdx-WArTxd9Rha0_sfjOfkpDGriBd7Tsjn4-yjfE7ni6eXcjpPHQgJqRaaWidtlkmb8wbQgpZaM2t4zqB2SBvXIK9zsEw4IZVj3ILiklFuEQWfkOvdXxc2MQZsqi74tQm_FdBqu0Q1eyhe90sM9tXO7r7tGuuD-1-d_wFAf1eX</recordid><startdate>201705</startdate><enddate>201705</enddate><creator>Bennett, Mike</creator><creator>Paice, Judith A</creator><creator>Wallace, Mark</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201705</creationdate><title>Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives</title><author>Bennett, Mike ; Paice, Judith A ; Wallace, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1671-9690bc7b447b53f1eb197992ba3521dce0fcfe3d51b26c678c23b1837203bee63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Analgesics, Opioid - therapeutic use</topic><topic>Humans</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - physiopathology</topic><topic>Pain - etiology</topic><topic>Pain - physiopathology</topic><topic>Pain Management</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bennett, Mike</creatorcontrib><creatorcontrib>Paice, Judith A</creatorcontrib><creatorcontrib>Wallace, Mark</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American Society of Clinical Oncology educational book</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bennett, Mike</au><au>Paice, Judith A</au><au>Wallace, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives</atitle><jtitle>American Society of Clinical Oncology educational book</jtitle><addtitle>Am Soc Clin Oncol Educ Book</addtitle><date>2017-05</date><risdate>2017</risdate><volume>37</volume><issue>37</issue><spage>705</spage><epage>713</epage><pages>705-713</pages><issn>1548-8748</issn><eissn>1548-8756</eissn><abstract>Pain remains common in the setting of malignancy, occurring as a consequence of cancer and its treatment. Several high-quality studies confirm that more than 50% of all patients with cancer experience moderate to severe pain. The prevalence of pain in cancer survivors is estimated to be 40%, while close to two-thirds of those with advanced disease live with pain. Progress has occurred in the management of cancer pain, yet undertreatment persists. Additionally, new challenges are threatening these advances. These challenges are numerous and include educational deficits, time restraints, and limited access to all types of care. New challenges to access are occurring as a result of interventions designed to combat the prescription drug abuse epidemic, with fewer clinicians willing to prescribe opioids, pharmacies reluctant to stock the medications, and payers placing strict limits on reimbursement. A related challenge is our evolving understanding of the risks of long-term adverse effects associated with opioids. And reflective of the opioid abuse epidemic affecting the general population, the potential for misuse or abuse exists in those with cancer. Guidelines have been developed to support oncologists when prescribing the long-term use of opioids for cancer survivors. The challenges surrounding the use of opioids, and the need for safe and effective alternative analgesics, are leading to intense interest in the potential benefits of cannabis for cancer-related pain. Oncologists are faced with questions regarding the types of cannabis available, differences between routes of administration, data concerning safety and efficacy, and legal and regulatory dynamics.</abstract><cop>United States</cop><pmid>28561731</pmid><doi>10.1200/edbk_180469</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1548-8748
ispartof American Society of Clinical Oncology educational book, 2017-05, Vol.37 (37), p.705-713
issn 1548-8748
1548-8756
language eng
recordid cdi_crossref_primary_10_1200_EDBK_180469
source MEDLINE; American Society of Clinical Oncology Online Journals; EZB-FREE-00999 freely available EZB journals
subjects Analgesics, Opioid - therapeutic use
Humans
Neoplasms - complications
Neoplasms - physiopathology
Pain - etiology
Pain - physiopathology
Pain Management
Risk Factors
title Pain and Opioids in Cancer Care: Benefits, Risks, and Alternatives
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T02%3A38%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pain%20and%20Opioids%20in%20Cancer%20Care:%20Benefits,%20Risks,%20and%20Alternatives&rft.jtitle=American%20Society%20of%20Clinical%20Oncology%20educational%20book&rft.au=Bennett,%20Mike&rft.date=2017-05&rft.volume=37&rft.issue=37&rft.spage=705&rft.epage=713&rft.pages=705-713&rft.issn=1548-8748&rft.eissn=1548-8756&rft_id=info:doi/10.1200/edbk_180469&rft_dat=%3Cpubmed_cross%3E28561731%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28561731&rfr_iscdi=true